凭借欧洲最大的制药团队之一,我们为全球企业和初创企业的制药公司提供专业知识,帮助他们加快增长和保持竞争优势。我们在制药行业的知识和专业技能非常丰富。基于对技术、科学、知识产权和监管环境的透彻理解,客户很重视我们务实的战略建议。
为我们的制药客户确保一个可持续的未来是我们的首要任务,我们通过多种方式来实现这一目标。我们定期挑战监管机构的决定,进行司法审查,并与备受推崇的争议解决专家进行创新合作。我们的许多律师都拥有科学学位和博士学位,或者曾在全球领先的制药公司内部工作过,这使他们具有竞争优势以及可靠的实践知识和洞察力 我们确保我们的客户遵守法规,建立战略联盟和临床试验,就供应和分销以及所有知识产权方面提供建议。
我们还提供重组、制造、产品组合剥离、收购、IPO和并购方面的专业知识。
全球制药公司依靠我们的专利诉讼律师的专业知识来解决进攻性和防御性的多辖区专利诉讼。同样,我们与制药公司合作,通过法院或国际仲裁解决商业纠纷。
我们的工作范围广泛,涵盖了其他专业领域,这些领域对于我们的客户成长以及有价值的资产的保护和商业化都是非常宝贵的。我们的知识产权许可和生命科学商业专家为制药客户的产品商业化的构建、起草和谈判提供建议。我们专业的生命科学公司团队通过战略融资解决方案 确保创新制药公司的未来,包括与知名天使投资者和风险资本家合作,从私人股本公司投资,以及通过战略资产处置、收购和并购交易进行控制股权收购。
We advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.
Press releaseApotex on the sale of six European subsidiaries in Belgium, Poland, the Netherlands, Czech Republic and Spain, to Aurobindo for EUR74 million. This highly complex transaction involved the share transfer of subsidiaries in multiple jurisdictions being co-ordinated and managed by our UK team. We simultaneously advised on a multitude of business separation, ongoing product supply agreements and IP licences for the European business to continue operating after being removed from the Apotex group.
Teva Pharmaceuticals Europe BV on its divestments of portfolios of generic pharmaceutical products (approximately 260 medicinal products) in 24 EU jurisdictions to multiple purchasers, in addition to advising Teva on the divestment of certain parts of its business. The divestments were a condition enforced by the European Commission to approve Teva's USD40.5 billion acquisition of Allergan plc’s global generics and have been run as a competitive auction process, resulting in five asset sales.
CITIC 21CN Co., Limited (HKEX: 0241) (now known as Alibaba Health Information Technology Limited), a member of CITIC Group (HKEX: 0267), on a HKD1.3 billion takeover by Alibaba Group (NYSE: BABA; HKEX: 9988) (one of China's largest e-commerce companies) and Yunfeng Capital (the venture capital firm set up by Alibaba Group founder, Jack Ma). Alibaba and Yunfeng obtained a whitewash waiver and took a controlling stake without triggering a mandatory general offer.
One of the largest suppliers of pharmaceutical suppliers in the Benelux on its successful defence against a software licensing claim for approx. EUR2 million.
Several pharmaceutical companies on merger control issues, R&D, cooperation agreements, co-marketing and related aspects.
最新新闻和观点
Licensing the Cabilly antibody manufacturing patents: are royalties payable on post-expiry sales?
European Court of Justice on advertising for biocidal products: ‘Skin-friendly’ is misleading and violates EU law
Regional Court of Hamburg: Prohibition of a bonus programme for nursing staff because of violation of Section 7 para. 1 sentence 1 of the German Drug Advertising Act (HWG)
Court of Appeal in Ireland grants interlocutory injunction restraining the launch of Teva’s generic apixaban product pending determination of appeal
作者 Eoin Martyn
Germany as a location for pharmaceutical businesses - quo vadis, 2024?
Strategy paper by the German Federal Government on improving the regulatory framework for the pharmaceutical industry in Germany